首页 > 市场调查报告书 > 製药

消化器

市场调查报告书

商品编码

1699448

嗜伊红性食道炎市场：市场规模、份额、前景、按药物类别、分销管道和地区分類的机会分析 - 2025 年至 2032 年

Eosinophilic Esophagitis Market, by Drug Class, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032

出版日期: 2025年03月04日 | 出版商:

Coherent Market Insights | 英文 207 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2025 年全球嗜伊红性食道炎市场规模估计为 2.391 亿美元，预计到 2032 年将达到 17.974 亿美元，2025 年至 2032 年的复合年增长率为 33.4%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	2.391亿美元
效能数据	从2020年到2024年	预测期	2025年至2032年
预测期：2025-2032年复合年增长率：	33.40%	2032年价值预测	17.974亿美元

数字。嗜伊红性食道炎各地区市场占有率（%）2025年

嗜伊红性食道炎是一种慢性疾病，可透过类固醇和质子帮浦阻断剂等抑酸药物治疗。类固醇有助于减轻发炎。外用类固醇以吸入或液体药物的形式给药。如果出现严重的吞嚥问题或体重减轻，则需要服用口服类固醇。质子帮浦阻断剂可改善逆流症状并减少发炎。

市场动态

人们对嗜伊红性食道炎治疗必要性的认识不断提高，将导致对治疗药物的需求增加。因此，主要市场参与者正在开发新的治疗方法来满足对 EoE 药物的需求。例如，全球生物製药公司赛诺菲 (Sanofi SA) 正在进行 Dupixent (dupilumab) 的 3 期临床试验，预计将于 2024 年完成。此外，改善 EoE 管理的创新产品的出现预计将推动全球市场的成长。例如，2021年12月，日本跨国工业工业株式会社收到了美国食品药物管理局（FDA）针对嗜伊红性食道炎接受TAK-721（Budesonide口服混悬液）发出的完整回覆函。 2021年6月，Etrasimod获得美国FDA颁发的孤儿药资格（ODD）。 Etrasimod 正在由美国生物製药公司 Arena Pharmaceuticals, Inc. 进行研究。此外，嗜伊红性食道炎盛行率的不断上升可能会促进市场成长。例如，根据2018年7月发表在《沙乌地医学杂誌》上的一项研究，嗜伊红性食道炎是一种新兴疾病，在沙乌地阿拉伯儿童的发生率正在上升。

本研究的主要特点

本报告对预测期（2025-2032 年）全球嗜伊红性食道炎市场规模进行了详细分析，以 2024 年为基准年。
它揭示了不同领域的潜在商机，并解释了该市场的有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
全球嗜伊红性食道炎市场的主要企业是根据公司亮点、产品系列、关键亮点、财务表现和策略等参数进行的分析。
本报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
全球嗜伊红性食道炎市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进入者和金融分析师。
相关人员可以透过分析全球嗜伊红性食道炎市场中使用的各种策略矩阵来简化决策。

热图分析
市场占有率分析
- Ellodi Pharmaceuticals.
- EsoCap AG
- GlaxoSmithKline plc.
- Teva Pharmaceutical Industries Ltd
- Cipla Limited
- Sun Pharmaceutical Industries Limited
- AstraZeneca Plc
- Sanofi SA
- Arena Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Revolo Biotherapeutics
- Allakos Inc.
- Bristol-Myers Squibb Co
- Calypso Biotech
- DBV Technologies
- Landos Biopharma, Inc.
- Glenmark Pharmaceuticals
- Alkem Laboratories Ltd.
- Quorum Innovations LLC
- Falk Pharma GmbH

第九章分析师建议

命运之轮
分析师观点
一致的机会图

第 10 章章节

参考
调查方法

简介目录

Product Code: CMI4909

Global Eosinophilic Esophagitis Market is estimated to be valued at USD 239.1 Mn in 2025 and is expected to reach USD 1,797.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 33.4% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 239.1 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	33.40%	2032 Value Projection:	USD 1,797.4 Mn

Figure. Eosinophilic Esophagitis Market Share (%), By Region 2025

Eosinophilic esophagitis is a chronic condition which is treated with the help of steroids and acid suppressants such as proton pump inhibitors. Steroids help control the inflammation. Topical steroids are administered as a inhaler or as a liquid. Oral steroids may be prescribed to treat people who have serious swallowing problems or weight loss. Proton pump inhibitors help with reflux symptoms and decrease inflammation.

Market Dynamics

Growing awareness regarding eosinophilic esophagitis leads to an increase in demand for treatment products. Thus, key market players are engaged in developing newer treatments and addressing the demand for EoE treatment products. For instance, Sanofi S.A. a global biopharmaceutical company engaged in conducting a phase 3 clinical trial for Dupixent (dupilumab) and is estimated to complete by 2024. Additionally, upcoming innovative products to improve the management of EoE are anticipated to drive the global market growth. For instance, in December 2021, Takeda Pharmaceutical Company Limited a Japanese multinational pharmaceutical company received a Complete Response Letter (CRL) for TAK-721 (budesonide oral suspension) from the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis. In June 2021, the U.S. FDA granted Orphan Drug Designation (ODD) for Etrasimod. Etrasimod had been investigated by Arena Pharmaceuticals, Inc. an American biopharmaceutical company. Moreover, an increase in the prevalence of eosinophilic esophagitis is likely boost the market growth. For instance, according to a study published in the Saudi Medical Journal in July 2018, eosinophilic esophagitis is an emerging disease and has an increasing incidence in children in Saudi Arabia.

Key features of the study:

This report provides an in-depth analysis of the global eosinophilic esophagitis market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global eosinophilic esophagitis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, strategies
Key companies covered as a part of this study include Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global eosinophilic esophagitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global eosinophilic esophagitis market

Detailed Segmentation:

Global Eosinophilic Esophagitis Market, By Drug Class:
- Corticosteroids
- Budesonide
- Jorveza
- Off-label budesonide
- Fluticasone
- Proton Pump Inhibitor (PPI)
- Omeprazole
- Esomeprazole
- Others
- Late Stage Pipeline Drugs
- Dupixent
- APT-1011
- Lirentelimab (AK002)
- Cendakimab
- Etrasimod
- TAK-721
- Omilancor (BT-11)
Global Eosinophilic Esophagitis Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Eosinophilic Esophagitis Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- GlaxoSmithKline plc
- Ellodi Pharmaceuticals
- EsoCap AG
- Teva Pharmaceutical Industries Ltd.
- Cipla Limited
- Sun Pharmaceutical Industries Limited
- AstraZeneca Plc
- Sanofi S.A.
- Arena Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Revolo Biotherapeutics
- Allakos Inc.
- Bristol-Myers Squibb Co
- Calypso Biotech
- DBV Technologies
- Landos Biopharma, Inc.
- Glenmark Pharmaceuticals
- Alkem Laboratories Ltd.
- Quorum Innovations LLC
- Dr. Falk Pharma GmbH

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Opportunities
Impact Analysis
Pipeline Analysis
Regulatory Scenario
Recent Product Approval/Launch
PEST Analysis
Epidemiology

4. Global Eosinophilic Esophagitis Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply and Demand Analysis
Key Developments

5. Global Eosinophilic Esophagitis Market, By Drug Class, 2020 - 2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
  - Budesonide
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
      - Jorveza
        
        1. Introduction
        2. Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
      - Off-label budesonide
        
        1. Introduction
        2. Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - Fluticasone
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
Proton Pump Inhibitor (PPI)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
  - Omeprazole
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - Esomeprazole
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - Others
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
Late Stage Pipeline Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
  - Dupixent
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - APT-1012
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - Lirentelimab (AK002)
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - Cendakimab
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - Etrasimod
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - TAK-721
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - Omilancor (BT-11)
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)

6. Global Eosinophilic Esophagitis Market, By Distribution Channel, 2020 - 2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)

7. Global Eosinophilic Esophagitis Market, By Region, 2020 - 2032, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2022 and 2029 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
  - U.K.
  - Germany
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis
- Ellodi Pharmaceuticals.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Strategies
- EsoCap AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Strategies
- GlaxoSmithKline plc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Teva Pharmaceutical Industries Ltd
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Cipla Limited
- Sun Pharmaceutical Industries Limited
- AstraZeneca Plc
- Sanofi S.A.
- Arena Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Revolo Biotherapeutics
- Allakos Inc.
- Bristol-Myers Squibb Co
- Calypso Biotech
- DBV Technologies
- Landos Biopharma, Inc.
- Glenmark Pharmaceuticals
- Alkem Laboratories Ltd.
- Quorum Innovations LLC
- Falk Pharma GmbH

9. Analyst Recommendation

Wheel of Fortune
Analyst View
Coherent Opportunity Map

10. Section

References
Research Methodology
About Us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

嗜伊红性食道炎市场：市场规模、份额、前景、按药物类别、分销管道和地区分類的机会分析 - 2025 年至 2032 年